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Background: Although half of all patients with heart failure (HF) have a normal or near-normal ejection fraction
and their prognosis differs little from that of patients with a reduced ejection fraction, the pathophysiology of HF
with preserved ejection fraction (HF-PEF) is still poorly understood, and its management poorly supported by clinical
trials. Sodium and fluid restriction is the most common self-care measure prescribed to HF patients for management
of congestive episodes. However, its role in the treatment of HF-PEF remains unclear. This trial seeks to compare the
effects of a sodium- and fluid-restricted diet versus an unrestricted diet on weight loss, neurohormonal activation,
and clinical stability in patients admitted for decompensated HF-PEF.
Methods/Design: This is a randomized, parallel trial with blinded outcome assessment. The sample will include
adult patients (aged ≥18 years) with a diagnosis of HF-PEF admitted for HF decompensation. The patients will
be randomized to receive a diet with sodium and fluid intake restricted to 0.8 g/day and 800 mL/day respectively
(intervention group) or an unrestricted diet, with 4 g/day sodium and unlimited fluid intake (control group), and
followed for 7 days or until hospital discharge. The primary outcome shall consist of weight loss at 7 days or discharge.
The secondary outcome includes assessment of clinical stability, neurohormonal activation, daily perception of thirst
and readmission rate at 30 days.
Discussion: Assessment of the effects of sodium and fluid restriction on neurohormonal activation and clinical course
of HF-PEF can promote a deeper understanding of the pathophysiology and progression of this complex syndrome.
Trial registration number: ClinicalTrials.gov identifier: NCT01896908 (date of registration: 8 August 2013).
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Heart failure (HF) with preserved ejection fraction (HF-
PEF), historically known as diastolic HF, is the clinical syn-
drome characterized by HF with normal or near-normal
systolic function [1]. More recent epidemiological studies* Correspondence: luisbeckdasilva@gmail.com
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unless otherwise stated.and registries have suggested that HF with reduced ejec-
tion fraction and HF-PEF are equally prevalent, with the
latter accounting for 40 to 71% (mean approximately 50%)
of cases [2,3].
The etiology and epidemiology of HF-PEF appear to be
distinct from those of HF with reduced ejection fraction.
Women and older adults with comorbidities such as hyper-
tension, diabetes, obesity, and coronary artery disease are
more commonly affected [4-8].
Despite the importance of HF-PEF, the pathophysiology
and treatment of this phenotype of HF are still poorly
understood. Thus far, the major clinical trials (I-Preserve,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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trial) [9-13] have failed to demonstrate the efficacy of any
specific treatment on mortality in these patients.
Currently, the mainstay of HF-PEF treatment is symp-
tomatic care and management of comorbidities that pre-
dispose patients to this condition, including hypertension,
diabetes, ischemia, and arrhythmias [14,15], and include
guidance on lifestyle modifications, such as restricted so-
dium and fluid intake [14,15]. Sodium restriction is the
self-care measure most commonly prescribed to patients
with HF, as it appears to be effective in reducing conges-
tion. However, the evidence base for this recommendation
is scarce, and the few studies that have been conducted
have yielded inconsistent findings [16-25]. Research has
focused on the physiological effects of intake of different
amounts of sodium, and few have assessed morbidity and
mortality outcomes [17-25]. Except for an observational
study by Lennie and colleagues [24] that compared num-
ber of hospital admissions and emergency department
visits between patients with a sodium intake of >3 g/day
versus <3 g/day, no studies have evaluated the effects of
sodium restriction in patients with HF-PEF; therefore, its
role in these patients remains unknown. Recently, how-
ever, Hummel and colleagues [26], investigating the effects
of the sodium restricted DASH diet, showed an increased
urinary aldosterone excretion during low-sodium diet in
patients with HF-PEF.
In an attempt to bridge the knowledge gap in patients
with decompensated HF-PEF, this trial seeks to compare
the effect of a sodium- and fluid-restricted diet versus an
unrestricted diet on weight loss, neurohormonal activa-
tion, and clinical stability at 7 days or at hospital discharge
in patients admitted for decompensation of HF-PEF.
Methods/Design
Study design and centers
This is a randomized, parallel trial with blinded outcome
assessment. The study population will comprise patients
with a diagnosis of HF-PEF who have presented to hospital
with HF decompensation. The study will be carried out at
Hospital de Clínicas de Porto Alegre (HCPA), Brazil, and
take place at the Emergency Department or other inpatient
units.
Inclusion and exclusion criteria
The sample will include adult patients with a diagnosis
of HF (and left ventricular ejection fraction >50%) within
36 hours of hospital admission for decompensation of
HF – defined as clinical signs of congestion, history of
dyspnea and orthopnea in the week before hospitalization,
and B-type natriuretic peptide (BNP) levels >100 pg/mL –
who agree to take part in the study and provide written
informed consent. Patients with an estimated glom-
erular filtration rate (Modification of Diet in Renal Diseaseformula) ≤30 mL/minute, those with cardiogenic shock,
HF due to valvular disease and those whose survival is
jeopardized by another ongoing condition and/or by diffi-
culty adhering to treatment (for example, due to dementia
or cognitive deficits) will be excluded.
Ethical considerations
All procedures were conducted in accordance with the
ethical standards for human subject research set forth in
the Declaration of Helsinki. Written informed consent
shall be obtained from all patients included in the trial.
The project was approved by the Research Ethics Commit-
tee of Hospital de Clínicas de Porto Alegre (registration
number 12–0437) and is registered in the ClinicalTrials.
gov database under identification number NCT01896908.
Sample size
Sample size calculations were carried out in WINPEPI
11.20 (Brixton Health, Israel). We used the weight loss
values reported in the studies of Aliti and colleagues [25]
and Cardoso and colleagues [27], which assessed weight
loss in patients with HF and systolic dysfunction admitted
for HF decompensation and congestion. For a significance
level of α = 0.05 and a statistical power of 80%, with a
standard deviation of 3 kg and a between-group difference
in weight corresponding to a weight loss of 2 kg in 7 days,
the minimum sample size will be 74 patients (37 random-
ized to each group).
Interventions
The control group (CG) will receive the standard hospital
diet, which provides approximately 4 g sodium (10 g salt)/
day and unlimited fluid intake. The intervention group
(IG) will receive an otherwise identical diet restricted to
0.8 g sodium (2 g salt)/day and 800 mL fluids/day until
the 7th day of admission or hospital discharge, whichever
comes first.
Study protocol
Patients who meet the inclusion criteria and are eligible
will be invited to take part in this trial during their
hospitalization. Data will be collected on sociodemo-
graphic parameters, clinical variables, results of laboratory
tests performed as part of routine patient care (creatinine,
urea, potassium, sodium, complete blood count, and BNP
on admission), current medications, body weight, and
clinical congestion score, and blood will be collected for
assessment of neurohormonal activation. Patients will
then be randomized to IG or CG.
Once allocation has been completed, the on-call dietitian
will be notified so as to change the participants’ meal plan
as appropriate. The same dietary prescription will be used
for participants in both the IG and CG: DIET AS PER
RESEARCH PROTOCOL. PATIENT WILL RECEIVE
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ALTER DIET. This practice will be implemented in
agreement with the medical staff and with the hos-
pital Department of Nutrition and Dietetics.
A daily check of medical records will be performed to
identify modification of any drug prescription. The
search for hypotensive episodes will be performed by
checking blood pressure every 6 hours and by question-
ing patients about symptoms of hypotension (dizziness,
fainting or lightheadedness) on a daily basis.
Outcomes assessment 30 days after discharge will be
carried out at the study facility by means of a face-to-
face encounter between the investigators and each partici-
pant, at which time a clinical assessment will be performed
and blood will be collected for analysis of neurohormonal
activation (Figure 1).
Randomization
The randomization will be performed through a simple
sequential randomization plan generated online, using
the www.randomization.com website.
Blinding
During hospitalization, the medical staff involved in pa-
tient care will be blind to group allocation. All clinical
assessments during hospitalization and at 30-day follow-
up will be conducted by a nurse also blinded to group
allocation.
Variables in the study
Clinical variables
Clinical congestion score The clinical congestion score
is an instrument composed of seven questions designed
to assess signs and symptoms of congestion, including
presence of pulmonary crackles, third heart sound, jugu-
lar venous distension, peripheral edema, hepatojugular
reflux, orthopnea, paroxysmal nocturnal dyspnea, and
New York Heart Association functional class. This score
ranges from 1 to 22 points, with higher scores being dir-
ectly indicative of worse congestion [28].
Blood pressure and heart rate Blood pressure and heart
rate will be measured by the trial investigators shortly
after randomization.
Estimation of glomerular filtration rate The Modifica-
tion of Diet in Renal Disease formula will be used for es-
timation of the glomerular filtration rate [29].
Left ventricular ejection fraction The left ventricular
ejection fraction will be assessed by means of echocardi-
ography, using the Teichholz method or, if available, the
Simpson method.Body weight Weight will be measured with participants
barefoot, wearing minimal clothing, and standing on the
center of a digital platform scale, and recorded in a
spreadsheet.
Medical history Data on the etiology of HF, history of
present illness, past medical history, comorbidities, and
current medications will be collected from patient re-
cords and checked during the patient interview.
Demographic variables
A structured questionnaire will be administered to all par-
ticipants for collection of demographic parameters (age,
sex, ethnicity), socioeconomic, and educational data.
Laboratory variables
Blood samples will be collected by a trained professional
at the time of study enrollment, at hospital discharge,
and 30 days after discharge. Samples will be centrifuged at
4°C, 3,670 rpm, for 10 minutes and stored in Eppendorf
tubes at −80°C for later analysis of neurohormonal activa-
tion (renin and aldosterone).
General blood work General blood work will comprise
of complete blood count, urea (ultraviolet kinetic assay),
serum creatinine (Jaffé method), plasma sodium and po-
tassium (ion selective electrode).
B-type (brain) natriuretic peptide Immunofluores-
cence methods will be used for quantitation of BNP
in plasma.
Renin A radioimmunoassay for measurement of angio-
tensin I generated by the action of renin on its substrate,
angiotensinogen, will be used for quantitation of plasma
renin activity.
Aldosterone A solid phase radioimmunoassay based on
aldosterone-specific antibodies will be used for quantita-
tion of serum aldosterone levels.
Primary outcome
The primary outcome measure shall consist of weight
loss at 7 days or discharge.
Secondary outcomes
The secondary outcome measures shall consist of:
a) Clinical stability, defined as improvement in
symptoms with no evidence of congestion (assessed
by congestion score); weight stable for 2 days, with
no loss or gain greater than 1 kg (daily weight
check); no intravenous HF drugs for 48 hours (daily
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Figure 1 CONSORT flowchart of the study. BNP, B-type natriuretic peptide; R, randomization; std., standard.
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medication record).
b) Neurohormonal activation: assessment of
neurohormonal activation shall include
measurement of serum renin, aldosterone, and
BNP levels on admission, at discharge, and at
30 days.
c) Daily perception of thirst: a visual scale (with values
ranging from 0 to 10) will be used daily to verify the
degree of thirst.
d) Hospital readmission rate for all-causes. Patients
shall be followed for 30 days after discharge.Statistical analyses
Continuous variables following a normal distribution will
be expressed as mean ± standard deviation; asymmetrically
distributed continuous variables will be expressed as me-
dian and interquartile range; and categorical variables will
be expressed as absolute and relative frequencies. For
between-group comparisons, Student’s t-test will be used
for normally distributed variables, and the Mann–Whitney
U test for asymmetrically distributed variables. A paired
t-test will be used for within-group analysis of body
weight and congestion score. The chi-square or Fisher’s
exact tests will be used to evaluate associations between
categorical variables. The generalized estimating equations
test with Bonferroni adjustment will be used for compari-
son between variables during the study period. The signifi-
cance level will be set at 5%, and all data will be analyzed
in SPSS 18.0 (SPSS Inc., Chicago, IL, USA).
For assessment of clinical stability, in accordance with
pre-established criteria, two blinded examiners (phys-
ician HF specialists not involved in the care of the study
participants) will analyze the outcome variables in both
groups.Discussion
During protocol, patients will receive the standard hos-
pital diet for both the control (normal diet) and inter-
vention group (low-sodium diet), modified only in the
amount of fluid offered to the intervention group. Dur-
ing the study, patients will be instructed to consume
only foods and beverages offered by the hospital. The
plate-waste method shall be used to measure sodium in-
take for 7 days or until hospital discharge, whichever comes
first. A trained investigator will assess dietary intake twice
daily: after lunch, for collection of information on intake
during breakfast, morning snack, and lunch; and after
dinner, for collection of information on intake during the
afternoon snack, dinner, and supper. In addition, a visual
scale (with values ranging from 0 to 10) will be used to
verify the degree of thirst.Trial status
The trial is ongoing. Thirteen patients have completed the
study protocol and additional patients are being recruited.
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